RU2002117649A - Фармацевтические композиции, содержащие золмитриптан - Google Patents
Фармацевтические композиции, содержащие золмитриптанInfo
- Publication number
- RU2002117649A RU2002117649A RU2002117649/15A RU2002117649A RU2002117649A RU 2002117649 A RU2002117649 A RU 2002117649A RU 2002117649/15 A RU2002117649/15 A RU 2002117649/15A RU 2002117649 A RU2002117649 A RU 2002117649A RU 2002117649 A RU2002117649 A RU 2002117649A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- composition according
- zolmitriptan
- intranasal administration
- buffer
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract 12
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 title claims abstract 8
- 229960001360 zolmitriptan Drugs 0.000 title claims abstract 8
- 239000000203 mixture Substances 0.000 claims abstract 5
- 239000007864 aqueous solution Substances 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 150000001860 citric acid derivatives Chemical class 0.000 claims 2
- 102000035038 5-HT1 receptors Human genes 0.000 claims 1
- 108091005478 5-HT1 receptors Proteins 0.000 claims 1
- 230000008484 agonism Effects 0.000 claims 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 1
- 229910000397 disodium phosphate Inorganic materials 0.000 claims 1
- 235000019800 disodium phosphate Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000003521 serotonin 5-HT1 receptor agonist Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (14)
1. Фармацевтическая композиция, пригодная для интраназального введения, которая содержит золмитриптан и фармацевтически приемлемый носитель, причем рН этой композиции меньше 7,0.
2. Фармацевтическая композиция по п.1, где рН композиция находится в диапазоне 4,5-5,5.
3. Фармацевтическая композиция по п.1 или 2, где данная композиция является забуференной.
4. Фармацевтическая композиция по п.3, где буфер является смесью лимонной кислоты и динатрийфосфата.
5. Фармацевтическая композиция по любому из пп.1-4, которая является стерильной.
6. Способ приготовления стерильной фармацевтической композиции по п.5, предусматривающий автоклавирование.
7. Способ лечения патологического состояния, в котором полезным является агонизм 5НТ1-рецепторов, предусматривающий введение эффективного количества фармацевтической композиции по любому из пп.1-5.
8. Применение золмитриптана для приготовления фармацевтической композиции по любому из пп.1-5.
9. Устройство для интраназального введения, содержащее фармацевтическую композицию по любому из пп.1-5.
10. Устройство для интраназального введения, содержащее фармацевтическую композицию по любому из пп.1-5, упакованное для защиты от света.
11. Водный раствор золмитриптана в буфере при рН менее 7,0.
12. Водный раствор золмитриптана в буфере при рН в диапазоне 4,5-5,5.
13. Цитратная соль золмитриптана.
14. Цитратная соль золмитриптана в водном растворе.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9928578.8 | 1999-12-03 | ||
| GBGB9928578.5A GB9928578D0 (en) | 1999-12-03 | 1999-12-03 | Pharmaceutical formulations |
| GB9928578.5 | 1999-12-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2002117649A true RU2002117649A (ru) | 2004-01-27 |
| RU2255736C2 RU2255736C2 (ru) | 2005-07-10 |
Family
ID=10865629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002117649/15A RU2255736C2 (ru) | 1999-12-03 | 2000-11-28 | Фармацевтические композиции, содержащие золмитриптан |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US6750237B1 (ru) |
| EP (1) | EP1237551B1 (ru) |
| JP (1) | JP2003515559A (ru) |
| KR (1) | KR100670092B1 (ru) |
| CN (1) | CN1222287C (ru) |
| AT (1) | ATE291914T1 (ru) |
| AU (1) | AU778092B2 (ru) |
| BR (1) | BRPI0016138B8 (ru) |
| CA (1) | CA2392050C (ru) |
| CZ (1) | CZ301528B6 (ru) |
| DE (1) | DE60019162T2 (ru) |
| EE (1) | EE05305B1 (ru) |
| ES (1) | ES2236001T3 (ru) |
| GB (2) | GB9928578D0 (ru) |
| HK (2) | HK1048442B (ru) |
| HU (1) | HU229458B1 (ru) |
| IL (2) | IL149578A0 (ru) |
| IS (1) | IS2135B (ru) |
| MX (1) | MXPA02005319A (ru) |
| NO (1) | NO322119B1 (ru) |
| NZ (1) | NZ518862A (ru) |
| PL (1) | PL200679B1 (ru) |
| PT (1) | PT1237551E (ru) |
| RU (1) | RU2255736C2 (ru) |
| SK (1) | SK287228B6 (ru) |
| UA (1) | UA75059C2 (ru) |
| WO (1) | WO2001039772A1 (ru) |
| ZA (1) | ZA200203704B (ru) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8465468B1 (en) | 2000-06-29 | 2013-06-18 | Becton, Dickinson And Company | Intradermal delivery of substances |
| GB9928578D0 (en) * | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Pharmaceutical formulations |
| SE0102855D0 (sv) * | 2001-08-27 | 2001-08-27 | Astrazeneca Ab | Method of treatment |
| WO2005115360A2 (en) * | 2004-05-11 | 2005-12-08 | Becton, Dickinson And Company | Formulations of anti-pain agents and methods of using the same |
| US8216610B2 (en) | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
| US20080287456A1 (en) * | 2004-05-28 | 2008-11-20 | Imaginot Pty Ltd | Oral Therapeutic Compound Delivery System |
| EP1812428A2 (en) * | 2004-11-19 | 2007-08-01 | Teva Pharmaceutical Industries Ltd | Zolmitriptan crystal forms |
| CN100341504C (zh) * | 2004-12-01 | 2007-10-10 | 鲁南制药集团股份有限公司 | 佐米曲普坦速释制剂 |
| US9757455B2 (en) * | 2005-11-28 | 2017-09-12 | Johnson & Johnson Consumer Inc. | Oral therapeutic compound delivery system |
| WO2008016678A2 (en) * | 2006-08-01 | 2008-02-07 | Sunesis Pharmaceuticals, Inc. | Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid |
| ATE502921T1 (de) * | 2006-10-19 | 2011-04-15 | Auspex Pharmaceuticals Inc | Substituierte indole |
| KR101517415B1 (ko) * | 2008-05-14 | 2015-05-07 | 에스케이바이오팜 주식회사 | 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물 |
| US9186359B2 (en) | 2010-10-15 | 2015-11-17 | Contera Pharma Aps | Combinations of serotonin receptor agonists for treatment of movement disorders |
| JP6121734B2 (ja) * | 2012-02-09 | 2017-04-26 | 久光製薬株式会社 | マイクロニードル用ゾルミトリプタン含有コーティング組成物及びマイクロニードルデバイス |
| SG11201406690SA (en) | 2012-04-18 | 2014-11-27 | Contera Pharma Aps | Orally available pharmaceutical formulation suitable for improved management of movement disorders |
| US11554229B2 (en) | 2013-03-26 | 2023-01-17 | OptiNose Inc. | Nasal administration |
| KR101624049B1 (ko) | 2014-10-29 | 2016-05-24 | 연세대학교 산학협력단 | 사카린을 이용한 용해도를 증가시킨 약제학적 조성물 |
| CN108135916B (zh) * | 2015-06-19 | 2022-01-28 | 北京科辉智药生物科技有限责任公司 | 手性特异性含硼化合物及其在治疗癌症或淀粉样变性中的应用 |
| WO2017122161A1 (en) | 2016-01-15 | 2017-07-20 | Cadila Healthcare Limited | An intranasal composition comprising 5ht1b/1d receptor agonists |
| WO2018011181A1 (en) | 2016-07-11 | 2018-01-18 | Contera Pharma Aps | Pulsatile drug delivery system for treating morning akinesia |
| WO2019126766A1 (en) * | 2017-12-21 | 2019-06-27 | Taiwan Liposome Co., Ltd. | Sustained-release triptan compositions and method of use the same through subdermal route or the like |
| US20210322343A1 (en) | 2020-04-15 | 2021-10-21 | Farzana Shaheen | Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9012672D0 (en) * | 1990-06-07 | 1990-08-01 | Wellcome Found | Therapeutic heterocyclic compounds |
| MC2210A1 (fr) * | 1990-06-07 | 1992-11-26 | Wellcome Found | Composes heterocycliques therapeutiques,leur utilisation et procede pour les preparer |
| GB9516145D0 (en) * | 1995-08-07 | 1995-10-04 | Wellcome Found | Improved chemical synthesis |
| KR20000022239A (ko) | 1996-07-11 | 2000-04-25 | 토마스 헤인 | 인돌 선택성 세로토닌 작용약을 함유한 내포 복합체 |
| GB2315673A (en) * | 1996-08-01 | 1998-02-11 | Merck & Co Inc | Treatment of migraine |
| US6461591B1 (en) * | 1997-02-05 | 2002-10-08 | Jago Research Ag | Medical aerosol formulations |
| GB9928578D0 (en) * | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Pharmaceutical formulations |
-
1999
- 1999-12-03 GB GBGB9928578.5A patent/GB9928578D0/en not_active Ceased
-
2000
- 2000-11-28 CA CA002392050A patent/CA2392050C/en not_active Expired - Lifetime
- 2000-11-28 CN CNB008163820A patent/CN1222287C/zh not_active Expired - Lifetime
- 2000-11-28 EE EEP200200283A patent/EE05305B1/xx unknown
- 2000-11-28 NZ NZ518862A patent/NZ518862A/en not_active IP Right Cessation
- 2000-11-28 AT AT00979765T patent/ATE291914T1/de active
- 2000-11-28 SK SK753-2002A patent/SK287228B6/sk not_active IP Right Cessation
- 2000-11-28 PT PT00979765T patent/PT1237551E/pt unknown
- 2000-11-28 RU RU2002117649/15A patent/RU2255736C2/ru active
- 2000-11-28 AU AU17157/01A patent/AU778092B2/en not_active Expired
- 2000-11-28 WO PCT/GB2000/004528 patent/WO2001039772A1/en not_active Ceased
- 2000-11-28 IL IL14957800A patent/IL149578A0/xx active IP Right Grant
- 2000-11-28 HK HK03100515.3A patent/HK1048442B/zh not_active IP Right Cessation
- 2000-11-28 JP JP2001541504A patent/JP2003515559A/ja active Pending
- 2000-11-28 HK HK03100621.4A patent/HK1048445B/en not_active IP Right Cessation
- 2000-11-28 BR BRPI0016138A patent/BRPI0016138B8/pt not_active IP Right Cessation
- 2000-11-28 DE DE60019162T patent/DE60019162T2/de not_active Expired - Lifetime
- 2000-11-28 KR KR1020027006849A patent/KR100670092B1/ko not_active Expired - Lifetime
- 2000-11-28 ES ES00979765T patent/ES2236001T3/es not_active Expired - Lifetime
- 2000-11-28 UA UA2002075443A patent/UA75059C2/ru unknown
- 2000-11-28 US US10/129,773 patent/US6750237B1/en not_active Expired - Lifetime
- 2000-11-28 PL PL357597A patent/PL200679B1/pl unknown
- 2000-11-28 EP EP00979765A patent/EP1237551B1/en not_active Expired - Lifetime
- 2000-11-28 CZ CZ20021901A patent/CZ301528B6/cs not_active IP Right Cessation
- 2000-11-28 HU HU0203597A patent/HU229458B1/hu unknown
- 2000-11-28 GB GB0214845A patent/GB2373726B/en not_active Expired - Lifetime
-
2002
- 2002-05-09 IL IL149578A patent/IL149578A/en unknown
- 2002-05-09 ZA ZA200203704A patent/ZA200203704B/xx unknown
- 2002-05-24 IS IS6394A patent/IS2135B/xx unknown
- 2002-05-28 NO NO20022525A patent/NO322119B1/no not_active IP Right Cessation
- 2002-05-29 MX MXPA02005319A patent/MXPA02005319A/es active IP Right Grant
-
2004
- 2004-05-27 US US10/854,959 patent/US7220767B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2002117649A (ru) | Фармацевтические композиции, содержащие золмитриптан | |
| TR200003158T2 (tr) | Jelleşebilen farmasötik bileşimler | |
| PT1227806E (pt) | Formulacao farmaceutica contendo tolterodina e sua utilizacao | |
| ATE103808T1 (de) | N-(3,4-dimethoxycinnamoyl)-anthranilsaeure enthaltende arzneimittelzusammensetzungen. | |
| ATE375341T1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| RU94041223A (ru) | Средство для лечения мотонейроновых заболеваний | |
| NO172580C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte n-(1-alkyl-3-hydroksy-4-piperidinyl)benzamider | |
| EA200000785A1 (ru) | Новые сульфонамидные производные в качестве ингибиторов рассасывания костной ткани и ингибиторов адгезии клеток | |
| MX9301197A (es) | Derivados de indol. | |
| RU2004111357A (ru) | Комбинированные агенты для лечения глаукомы | |
| SE0102055D0 (sv) | New Compounds | |
| RU2209064C2 (ru) | Новое применение в медицинских целях | |
| TR200001519T2 (tr) | İnsanlardaki Spermatozoa'nın konsantrasyonu ve/veya hareket kabiliyetini artırmak için uygulanması gerekli yöntem ve ilaç terkipleri | |
| ATE440838T1 (de) | Pharmazeutisch aktive sulfonylaminosäurederivate | |
| US5270050A (en) | Paracetamol-based pharmaceutical composition | |
| RU94031479A (ru) | Новое применение производных аминокислот, способ лечения, фармацевтическая композиция | |
| BR9911756A (pt) | Composto, uso de um secretagogo do hormÈnio do crescimento ou um seu sal farmaceuticamente aceitável, composição farmacêutica, método para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero, e, uso de um composto | |
| NO950177D0 (no) | Farmakologisk aktive erivater | |
| TR200102087T2 (tr) | Yeni morfolinbenzamid tuzları | |
| EA199801015A1 (ru) | Производные пиперидинуксусной кислоты и их применение при лечении тромботических нарушений | |
| BR9906975A (pt) | Composto, uso do mesmo, composição farmacêutica, e, processo para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero | |
| AR005724A1 (es) | Derivados de ureido biologicamente activos utiles en el tratamiento de esclerosis multiple | |
| TNSN94110A1 (fr) | Procede de preparation de compositions orales contenant des quinolones | |
| RU99108789A (ru) | Ингибитор субэпителиального помутнения роговицы | |
| KR910002789A (ko) | 아크릴산염, 이것의 제조방법, 이것을 함유한 제약조성물 및 의약에서 이것을 사용하는 방법 |